Focus on CNS conformational diseases and oncology, using a combination of antibodies produced to non-covalent complexes of peptide sequences, presented as liposomes. Technical and corporate overviews of company in Lausanne, Switzerland.
Studying the possibilities of using an immunotherapeutic approach for melanoma, breast and colorectal and tumors. Includes results of clinical research, FAQ, contact form, and profile of research partners in Canada.
Develops organic chemistry and immunotherapy technology to produce synthetic therapeutic vaccines targeting proliferative tumors. Resources for patients and professionals and investors, with profile of company based in Edmonton, Alberta. (Nasdaq: BIOM)
Offers products for diagnosis, imaging and treatment of tumors, especially in lung. Technologies in sputum sample and pap smear screening, certifying cell lines, inflammatory focus imaging, Cu-TCPP treatment in pre-clinical development at Albuquerque, New Mexico.
Company focused on the discovery and development of anti-cancer drugs through synthetic biology of natural polyketides and rapamycin analogues. Describes technology, pipeline, and facilities near Saffron Walden, England.
Researches and develops novel therapeutic and diagnostic products to treat chronic debilitating diseases such as cancer, central nervous system disorders and autoimmune diseases. Based in Massachusetts. (Nasdaq: BLSI).
Introduction the mechanisms, with resources in oncology, vascular medicine and immunolgical disease, including possible therapies and links to related organizations, presented by Genentech, Inc.
Start-up focusing on the discovery, development and commercialisation of novel treatments for tumors and neurodegenerative diseases. Includes investor information, technology in GM-HSV targeting glioma and clinical trials in Glasgow, UK.
Preclinical-stage biopharmaceutical company that designs, develops and commercializes technologies for cancer metastasis research and treatment. Worldwide news, products and contacts in Bizkaia, Spain.
Resource treatments aimed at chronic management, focusing on anti-angiogenesis, apoptosis, B-cell biology and HER signaling. Includes sections for professionals, customers and patients, with contacts in South San Francisco, California.
Focusing on the development of delivery systems to target solid tumors, such as prostate with nanoencapsulated biotherapeutics. Includes brief overview of concepts from Chaska, Minnesota.
Development and commercialization of vaccines, and treatments, such as telomere homologs and angiogenesis inhibition. Includes product pipeline, clinical trials, corporate profile and contacts in Carlsbad, California.
Engaged in the design, development and commercialization of tumor screening systems. Information for investors, clinicians and patients, about their technologies, product timeline, and headquarters in Chicago, Illinois.
Conducts research and development for marketing cell-based vaccines and human monoclonal antibody against CD55 in tumour cells. Includes explanation of products in pipeline, and clinical studies in phase II of prostate cancer vaccine at Bournemouth, and their contacts in London, UK.
Company developing gene therapy system, using the E. coli enzyme, purine nucleoside phosphorylase, to induce suicide in tumor cells. Includes technology background, research, patents, publications, key staff, and contacts in Birmingham, Alabama.
Developing stem cell products and therapies for hepatic diseases, offering human hepatocytes and microsomes for pre-clinical research. Overview of services, references, related links and contacts in Pathumthani, Thailand.
Develops, produces and licenses natural products, such as quassinoids and taxanes. Includes introduction to targeted oncology, investment data and profile of company in Boulder, Colorado. (Nasdaq: NPRO)
Oncology studies in small molecule histone deacetylase and topoisomerase II inhibitors, with clinical trials in solid tumours, CNS and extravasation. Technology and profile of company with facilities in Copenhagen and Abingdon, England.
